Boston Scientific Corporation (BSX) Balance Sheet

Total liabilities also rose over the period, but the debt-to-equity ratio held in a 0.42 to 0.54 band, which suggests growth has been financed in roughly balanced proportions. The gain in retained earnings from $1.6B to $8.4B shows that internally generated capital is now a larger share of equity, a shift that may reduce reliance on external financing over time. Investors should monitor whether asset growth continues to be driven by acquired goodwill, since that would make the quality of the expansion dependent on deal execution.

The debt load has not expanded in step with assets, which may indicate that acquisitions have been funded partly from earnings and equity rather than purely from new borrowing. Leverage is moderate rather than conservative, and the 2026Q1 dip to 0.42 followed by a return to 0.46 in 2026Q3 suggests debt management is responsive to cash balances. Refinancing and interest coverage terms are not provided in the supplied data, so the durability of this structure cannot be fully assessed.

The step-up in goodwill during 2024Q3 and subsequent quarters is consistent with tuck-in acquisition activity, and the asset base is clearly acquisition-driven rather than organically built. Net PPE of about $4.2B to $4.6B is modest relative to the company's size, which suggests a relatively asset-light manufacturing footprint for a device business. Impairment risk on goodwill is a material tail consideration, since a weakening in acquired franchise performance could trigger write-downs that would reduce equity sharply.

The current ratio remains above 1.0, which indicates current assets still cover current liabilities, but the sharp decline in cash suggests the company has been deploying liquidity into acquisitions and operations. A cash position of roughly $0.6B against total debt of $12.0B means the company depends on continued operating cash flow and credit access rather than a large cash reserve. The data does not show undrawn credit facilities, so the true liquidity cushion cannot be confirmed from the supplied figures.

The rising retained earnings base improves equity quality, since it reflects accumulated profitability rather than dilution. Stock-based compensation and share repurchase activity are not isolated in the supplied balance sheet data, so the net dilution effect cannot be confirmed. Investors should monitor whether recent earnings volatility, including the EPS swing noted in prior income analysis, translates into a sustained retained earnings trajectory.